Brief: IGM Biosciences Announces Refocusing of Sanofi Collaboration
17/04/2024 13:40
April 17 (Reuters) - IGM Biosciences Inc IGMS.O :
* IGM BIOSCIENCES ANNOUNCES REFOCUSING OF SANOFI
COLLABORATION
* IGM BIOSCIENCES INC: AGREEMENT WITH SANOFI TO CREATE AND
DEVELOP
IGM AGONIST ANTIBODIES WILL NOW FOCUS EXCLUSIVELY ON
IMMUNOLOGY/INFLAMMATION TARGETS
* IGM BIOSCIENCES INC: WILL RETAIN GLOBAL RIGHTS TO ITS
PROPRIETARY TECHNOLOGY RELATED TO ONCOLOGY TARGETS NOMINATED BY
SANOFI UNDER COLLABORATION
* IGM BIOSCIENCES: UNDER AGREEMENT, WILL BE ELIGIBLE TO
RECEIVE UP
TO $1,065 MILLION IN AGGREGATE DEVELOPMENT, REGULATORY AND
COMMERCIAL MILESTONES/TARGET
Source text for Eikon: ID:nGNX3BMkgB
Further company coverage: IGMS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGM Biosciences
See all newsU.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex
U.S. STOCKS ON THE MOVE-Snap, Solventum, GlobalFoundries
IGM Biosciences rises on buyout deal with Concentra Biosciences
Brief: Igm Biosciences Enters Into Agreement To Be Acquired By Concentra Biosciences For $1.247 In Cash Per Share Plus A Contingent Value Right
IGM Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary